Globus Medical filings document formal disclosures for a medical device company focused on musculoskeletal solutions and enabling technologies. Recent Form 8-K reports furnish quarterly and annual operating results, preliminary sales information, financial guidance and related press releases covering net sales, earnings measures, cash flow and segment commentary.
The company’s proxy materials cover board elections, governance practices, executive compensation, equity awards and annual meeting matters. Other current reports document leadership transitions, director departures and related governance events, tying the filing record to Globus Medical’s operating performance, management structure and public-company reporting obligations.
Globus Medical Inc. was the subject of BlackRock, Inc.'s amended ownership report. As of September 30, 2026, BlackRock reported beneficial ownership of 10,704,283 shares of Class A Stock, equal to 8.0% of the class. It reported sole voting power over 10,335,190 shares and sole dispositive power over 10,704,283 shares; shared voting and dispositive power were both zero. The report covers specified BlackRock business units and affiliates, excluding units whose holdings are disaggregated.
GLOBUS MEDICAL INC (GMED) director James R. Tobin reported exercising options and selling shares on September 15, 2026. He exercised options for 15,000 shares at an exercise price of $53.75 and 15,000 shares at $63.68, receiving 30,000 Class A Common shares, then sold 30,000 shares at a weighted average price of $74.5834 in multiple transactions at prices ranging from $74.33 to $74.96. The options exercised were fully vested grants from January 26, 2024 and January 27, 2022, and no Rule 10b5-1 trading plan is reported.
Globus Medical Inc (GMED) is the issuer for a planned sale of restricted securities disclosed under Rule 144 for the account of director James Robert Tobin Jr. The notice covers a proposed sale of 30,000 shares of Common Stock through Raymond James & Associates, Inc. on September 15, 2026 on the NYSE.
The filing describes the planned disposition as a cashless option exercise with the issuer listed as the party involved in the option exercise. The aggregate dollar amount associated with the 30,000 shares is stated as $2,236,000.
GLOBUS MEDICAL INC (GMED) director Stephen T. Zarrilli reported an option exercise and same-day stock sale. He exercised 25,000 stock options for Class A Common Stock at an exercise price of $53.27 per share, then sold 25,000 shares of Class A Common Stock at a weighted average price of $87.0386 per share in multiple transactions. The options exercised were fully vested and, after the exercise, the reported option position in this grant was 0 shares.
GLOBUS MEDICAL INC (GMED) received a Rule 144 notice for a proposed sale of restricted or control securities. A director, Stephen T. Zarrilli, plans to sell 25,000 shares of common stock through Raymond James & Associates on the NYSE, with an indicated aggregate value of $2,176,000.00. The shares are to be issued via a cashless option exercise with the issuer as of 08/18/2026.
Globus Medical, Inc. reported higher net sales of $789,612 (in thousands) for the quarter ended June 30, 2026 and $1,549,466 (in thousands) for the first half of 2026. Operating income was $182,432 and $332,820 (in thousands), supported by lower cost of sales, acquisition-related and restructuring expenses.
Net income was $151,569 for the quarter and $275,871 (in thousands) year-to-date, with diluted EPS of $1.10 and $2.00, respectively. Prior-year results included a bargain purchase gain of $110,561 (in thousands) from the Nevro acquisition versus $1,118 (in thousands) recognized in 2026.
Cash and cash equivalents totaled $507,745 (in thousands), alongside short-term marketable securities of $87,397 (in thousands) and long-term marketable securities of $245,358 (in thousands). Operating activities generated $412,105 (in thousands) of cash in the first half. The company repurchased 1.6 million Class A shares for $136.1 million under its $500.0 million authorization and had no outstanding borrowings under its $400.0 million revolving credit facility or 0.375% senior convertible notes. Litigation reserves included a previously recorded $43.1 million provision for the Pimenta matter, while other significant cases continue without additional accruals beyond legal fees.
Globus Medical reported second quarter 2026 results with worldwide net sales of $789.6 million, up 5.9% year over year, or 5.6% on a constant currency basis. U.S. net sales grew 3.0%, while international net sales increased 18.0% as reported and 16.2% on a constant currency basis, supported by growth in US Spine and International Spine.
GAAP net income for the quarter was $151.6 million, and GAAP diluted EPS was $1.10, down 26.2% from the prior-year period primarily because the prior year included a $110.5 million bargain purchase gain related to the Nevro acquisition. On a non-GAAP basis, diluted EPS rose 55.8% to $1.34, and Adjusted EBITDA reached $279,839 (in thousands), or 35.4% of net sales, alongside 200 basis points of adjusted gross margin expansion.
For the first six months of 2026, total net sales grew 15.3% year over year. Net cash provided by operating activities was $412,105 (in thousands), supporting free cash flow of $339,322 (in thousands) and total cash, cash equivalents and marketable securities of $840,500 (in thousands). The company reaffirmed 2026 revenue guidance of $3.18–$3.22 billion and raised its non-GAAP fully diluted EPS outlook to $4.95–$5.05 from $4.70–$4.80.
Globus Medical Inc. director David D. Davidar reported a bona fide gift of 2,500 shares of Class A Common Stock on July 27, 2026, at $0.00 per share. After the gift, he directly holds 507,675 shares and has indirect ownership of 165,967 shares held in the Davidar Family Irrevocable Trust U/A 8/6/09 for the benefit of his spouse and children, with his spouse serving as trustee. The filing indicates this transaction was not made under a Rule 10b5-1 trading plan.
Globus Medical director David D. Davidar reported an exercise-and-sell transaction in Class A common stock. He exercised stock options for 25,000 shares at $26.27 per share and sold 25,000 shares in an open-market transaction at a weighted average price of $80.7629 per share.
Following these moves, Davidar directly holds 510,175 shares of Class A common stock. In addition, a family irrevocable trust established on August 6, 2009 holds 165,967 shares for the benefit of his spouse and children, with his spouse serving as trustee.
Globus Medical director Ann D. Rhoads exercised stock options to acquire 25,000 shares of Class A Common Stock at $26.27 per share. These options were granted on January 30, 2017 and were fully vested at exercise. Following the transaction, she directly owns 40,384 shares, and this filing shows no related share sales.